Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18824382 | 0.85 | HDAC6 (0.59) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL21215382 | 0.82 | HDAC6 (0.47) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL19030812 | 0.82 | HDAC4 (0.57) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL19861928 | 0.79 | HDAC6 (0.45) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL2306387 | 0.79 | HDAC6 (0.54) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL16104094 | 0.79 | HDAC6 (0.61) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL3156822 | 0.78 | L3MBTL1 (0.70) | BRD4 | |
| SCHEMBL2225015 | 0.78 | HDAC6 (0.53) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL12377809 | 0.78 | HDAC6 (0.59) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL6170178 | 0.78 | HDAC6 (0.53) | HDAC6HDAC4HDAC1HDAC8HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10980233-B2 | Oxadiazole compound and use thereof as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20190230928-A1 | OXADIAZOLE COMPOUND AND USE THEREOF AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980233-B2 | Oxadiazole compound and use thereof as pesticides | RXFP3, OXER1, OXA1L | HDAC6 1746/4885HDAC4 1699/4885BRD4 1508/4885 |
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC6 1474/4885HDAC4 1441/4885BRD4 972/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | HDAC6 1763/4885HDAC4 2773/4885BRD4 390/4885 |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | HDAC6 975/4885HDAC4 634/4885BRD4 1378/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC6 1474/4885HDAC4 1441/4885BRD4 972/4885 |
| US-20190230928-A1 | OXADIAZOLE COMPOUND AND USE THEREOF AS PESTICIDES | RXFP3, OXER1, OXA1L | HDAC6 1746/4885HDAC4 1699/4885BRD4 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.